Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Blood (2025) 146 (Supplement 1): 480.

https://doi.org/10.1182/blood-2025-480

Published: 2025

Journal Articles

Sarcopenia and body composition predict survival and reveal immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma

Blood (2025) 146 (Supplement 1): 7676.

https://doi.org/10.1182/blood-2025-7676

Published: 2025

Journal Articles

Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T-cell therapy in relapsed/refractory multiple myeloma

Nora Grieb, Thomas Wiemers, Patrick Born, David Fandrei, Luise Fischer, Maximilian Ferle, Song-Yau Wang, Madlen Jentzsch, Carmen Herling, Klaus Metzeler, Marco Herling, Simone Heyn, Uwe Platzbecker, Vladan Vucinic, Thomas Neumuth, Georg-Nikolaus Franke, Maximilian Merz

Blood (2025) 146 (Supplement 1): 5853.

https://doi.org/10.1182/blood-2025-5853

Published: 2025

Journal Articles

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Blood (2025) 146 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2025-1949

Published: 2025

Journal Articles

Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up

Blood (2025) 146 (Supplement 1): 5117.

https://doi.org/10.1182/blood-2025-5117

Published: 2025

Journal Articles

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Evgenii Shumilov, Débora-Michèle Grote Urtubey, Marcel Teichert, Maximilian Seib, Rebecca Wurm-Kuczera, Joseph Kauer, Friedrich-Linus Roessiger, Tobias Tix, Alexander Hölscher, Philipp Gödel, Christoph Brey, Paolo Mazzeo, Zoi Saxonis, Belana Kuhn, Vanja Zeremski, Franziska Brunner, Susanne Ghandili, Enver Aydilek, Markus Maulhardt, Philipp Nakov, Gregor Friedrich, Christian Schultze-Florey, Giuliano Filippini Velazquez, Igor Age Kos, Anna Ossami Saidy, Christoph Kimmich, Maika Klaiber-Hakimi, Philipp Berning, Andrea Kerkhoff, Bertram Glass, Isabelle Krämer, Lorenz Thurner, Mathias Lutz, Florian Heidel, Vladan Vucinic, Christiane Pott, Andreas Viardot, Gerald Wulf, Thomas Weber, Dimitrios Mougiakakos, Francis Ayuk, Udo Holtick, Sascha Dietrich, Niklas Gebauer, Ulf Schnetzke, Mathias Hänel, Martin Dreyling, Peter Dreger, Björn Chapuy, Fabian Müller, Bastian von Tresckow, Georg Lenz

Blood (2025) 146 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2025-5473

Published: 2025

Journal Articles

Spatiotemporal and genetic tracking of long-term persisting CAR-T cells following ciltacabtagene autoleucel treatment for multiple myeloma reveals molecular insights into late-onset toxicities

Blood (2025) 146 (Supplement 1): 690.

https://doi.org/10.1182/blood-2025-690

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7095.

https://doi.org/10.1182/blood-2024-202101

Published: 2024

Journal Articles

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

Blood (2024) 144 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2024-197901

Published: 2024

Journal Articles

Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

Blood (2024) 144 (Supplement 1): 4688.

https://doi.org/10.1182/blood-2024-210233

Published: 2024

Journal Articles

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Jule Ussmann, Clara Wall, Lara Bischof, Jacob Jendro, Dominic Brauer, Donata Backhaus, Klaus H Metzeler, Marco Herling, Carmen Herling, Vladan Vucinic, Georg-Nikolaus Franke, Maximilian Merz, Timm Denecke, Uwe Platzbecker, Sebastian Schwind, Hans-Jonas Meyer, Madlen Jentzsch

Blood (2024) 144 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2024-199943

Published: 2024

Journal Articles

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Vladan Vucinic, David Fandrei, Janine Kirchberg, Enrica Bach, Mandy Brueckner, Kathleen Friedrich, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Simone Heyn, Uwe Platzbecker, Maximilian Merz

Blood (2024) 144 (Supplement 1): 2094.

https://doi.org/10.1182/blood-2024-207117

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Blood (2024) 144 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2024-210451

Published: 2024

Journal Articles

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2024-211410

Published: 2024

Journal Articles

Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Jacob Jendro, Lara Bischof, Jule Ussmann, Tung Pham Thanh, Donata Backhaus, Dominic Brauer, Vladan Vucinic, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Maximilian Merz, Klaus H Metzeler, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood (2024) 144 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2024-207490

Published: 2024

Journal Articles

Prognostic Value of Baseline and Early Response FDG-PET/CT Combined with Cellular Dynamics in Patients with Refractory and Relapsed Mantle Cell Lymphoma (MCL) Undergoing Chimeric Antigen Receptor (CAR)-T Cell Therapy

Blood (2024) 144 (Supplement 1): 6343.

https://doi.org/10.1182/blood-2024-206686

Published: 2024

Journal Articles

Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 708.

https://doi.org/10.1182/blood-2024-198638

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Sarcopenia and body composition predict survival and reveal immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma

Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T-cell therapy in relapsed/refractory multiple myeloma

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Spatiotemporal and genetic tracking of long-term persisting CAR-T cells following ciltacabtagene autoleucel treatment for multiple myeloma reveals molecular insights into late-onset toxicities

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Prognostic Value of Baseline and Early Response FDG-PET/CT Combined with Cellular Dynamics in Patients with Refractory and Relapsed Mantle Cell Lymphoma (MCL) Undergoing Chimeric Antigen Receptor (CAR)-T Cell Therapy

Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only